Hypnion bags $20M in second venture round

The neuroscience drug discoverer Hypnion has raised $20 million in an extension of its second round of venture capital. MPM Capital, Advanced Technology Ventures, Forward Ventures, Flagship Ventures, Oxford Bioscience Partners, GIMV, S.R. One Limited, JAFCO, Alexandria Real Estate Equities, and Mintz Levin Investments all participated in the round. Hypnion says the money will move its lead insomnia drug into Phase II trials.

- read this release for more information